Formulary Search
Search Results : Bipolar disorder (adults) (Sodium valproate (NON childbearing potential) - Bipolar disorder (adults))
Show Icon and Status Keys
- Crushable tablets
- Enteric coated tablets
- Granules (slow release)
- Modified release capsules
- Modified release tablets
- Oral solution
Off-label use. Licesned product is valproic acid (valproate semisodium).
Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.
See separate formulary entry for sodium valproate in people WITH childbearing potential - important pregnancy-prevention requirement.
- Oral solution
- Oro-dispersible tablets
- Tablets
Oro-dispersible tablets are more cost effective than oral solution. Reserve oral solution for use in patients where the required dose is not available in an oro-dispersible form.
- Modified release tablets
- Oral suspension
- Tablets
For use in patients who are unresponsive to lithium.
Initiation and stabilisation by the mental health specialist for at least 1 month before any request for transfer of care to primary care.
- Modified release tablets
- Tablets
Prescribe by BRAND. Lithium carbonate and lithium citrate are not equivalent.
Initiation and stabilisation by the specialist mental health team for at least 1 month before any request to transfer prescribing responsibility to primary care.
SASH- (Tablets non-formulary)
- Liquid
- Oral solution
Prescribe by BRAND. Lithium carbonate and lithium citrate are not equivalent.
Initiation and stabilisation by the specialist mental health team for at least 1 month before any request to transfer prescribing responsibility to primary care.
- Tablets
For the prevention of recurrence in bipolar disorder.
Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
For the prevention of recurrence in bipolar disorder.
Initiation by a Mental Health specilalist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube.
- Immediate release tablets
For bipolar with mania / depression.
Initiation and stabilisation by a Mental Health specialist for a minimum of 1 month before any request for transfer of prescribing responsibility.
- Modified release tablets
For bipolar with mania / depression.
Modified release tablets are reserved for use when immediate release tablets are not suitable.
Modified release quetiapine MAY be continued in Primary Care (after a 3-month period of stabilisation by a Mental Health specialist) where the use of immediate release tablets would risk destabilising the patient.
- Gastro-resistant tablets
Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.
See separate formulary entry for valproic acid in people WITH childbearing potential - important pregnancy-prevention requirement.
- Crushable tablets
- Enteric coated tablets
- Granules (slow release)
- Modified release capsules
- Modified release tablets
- Oral solution
Off-label use. Licesned product is valproic acid (valproate semisodium).
Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.
Pregnancy prevention requirement - refer to additional information on the PAD (click on drug name to access)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Gastro-resistant tablets
Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.
Pregnancy prevention requirement - refer to additional information on the PAD (click on drug name to access)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136